Related Experiment Video

Updated: Aug 15, 2026

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

Type A behavior: its diagnosis, cardiovascular relation and the effect of its modification on recurrence of coronary

M Friedman1

  • 1Meyer Friedman Institute, Mount Zion Hospital and Medical Center, San Francisco, California 94120.

The American Journal of Cardiology
|August 2, 1989
PubMed

Insights

Type A behavior is linked to coronary artery disease, hypertension, and migraine. Counseling Type A individuals significantly reduces coronary events and mortality.

Area of Science:

  • Cardiology
  • Behavioral Medicine
  • Psychophysiology

Background:

  • Type A behavior pattern is a potential risk factor for cardiovascular diseases.
  • The association between Type A behavior and hypertension, migraine, and coronary artery disease warrants further investigation.
  • Understanding the pathophysiological mechanisms linking Type A behavior to clinical outcomes is crucial.

Purpose of the Study:

  • To review the relationship between Type A behavior and clinical conditions such as coronary artery disease, hypertension, and migraine.
  • To describe the humoral and lipid changes associated with Type A behavior.
  • To outline diagnostic methods for Type A behavior and strategies for its management.

Main Methods:

  • Literature review of studies on Type A behavior and its health implications.
  • Description of pathophysiological pathways linking Type A behavior to cardiovascular events.
  • Summary of diagnostic criteria and therapeutic interventions for Type A behavior.

Main Results:

  • Type A behavior is associated with humoral and lipid derangements.
  • This behavior can accelerate the onset and severity of clinical coronary artery disease.
  • Type A behavior counseling led to a significant reduction in coronary morbidity and mortality.

Conclusions:

  • Type A behavior is a significant risk factor for cardiovascular disease.
  • Effective diagnostic and management strategies for Type A behavior can mitigate cardiovascular risks.
  • Interventions targeting Type A behavior show promise in reducing coronary events and mortality.

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...